25 July 2025 - The primary outcome was met in 27.8% of patients, confirming the efficacy in children and adolescents with persistent or chronic immune thrombocytopenia.

Sobi North America today announced that the US FDA approved Doptelet (avatrombopag) for the treatment of thrombocytopenia in paediatric patients one year and older with persistent or chronic immune thrombocytopenia who have had an insufficient response to a prior therapy.

Read Sobi press release